Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesDiseases and Disorders of the Ear, Nose, Mouth and ThroatDRG 148-ear-nose-mouth-and-throat-malignancy-without-cc-mcc
    Ask Trek AI about this page

    Ear, Nose, Mouth and Throat Malignancy without CC/MCC: Inpatient Reimbursement Overview

    DRG 148 encompasses inpatient admissions for malignancies of the ear, nose, mouth, and throat without Complication or Comorbidity or Major Complication or Comorbidity; it covers primary tumor resections, limited reconstruction, and diagnostic procedures. Accurate classification matters because this Diagnosis-Related Group defines the bundled Medicare reimbursement for uncomplicated head and neck cancer hospitalizations and affects hospital revenue and coding accuracy.

    Customize your policy alerts

    Sign up for drg 148 policy alerts

    Get alerted when payer policies referencing 148 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 148 Overview

    DRG 148 covers inpatient stays for malignant neoplasms of the ear, nose, mouth, and throat without Complication or Comorbidity or Major Complication or Comorbidity. Typical cases include primary resections, limited reconstructive procedures, and diagnostic interventions for head and neck cancers when no additional acute complicating conditions are present. This Diagnosis-Related Group is important for Medicare payment because it groups clinically similar resource use and establishes the base inpatient reimbursement for these straightforward oncologic admissions. Understanding the clinical scope helps hospitals classify cases for appropriate Medicare Severity Diagnosis-Related Group assignment and payment.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Neoadjuvant and perioperative therapy trials assessing the impact of chemotherapy and/or radiation given before definitive surgery: these studies enroll patients with operable head and neck squamous cell carcinomas of the ear, nose, mouth, and throat who are scheduled for tumor resection and neck dissection. Investigators measure tumor downstaging, margin status, rates of organ-preserving surgery, and perioperative complication rates to determine whether preoperative therapy improves surgical outcomes. Results are relevant to providers and payers because improved downstaging can reduce extent of surgery, length of stay, and downstream costs associated with extensive reconstructions and complications.
    • Comparative effectiveness studies of surgical approaches and perioperative management for primary resection without major complications: these pragmatic trials or registry analyses compare techniques such as transoral robotic or endoscopic resections versus open approaches, different reconstruction strategies, and enhanced recovery after surgery (ERAS) protocols in patients without major comorbidities. They focus on short-term inpatient outcomes (operative time, transfusion, SSI, LOS, readmissions) and functional measures (swallowing, speech) to identify approaches that maintain oncologic control while minimizing resource use. Payers and hospital teams use this evidence to guide choices that balance clinical effectiveness with costs and to standardize pathways that reduce variability in reimbursement for DRG 148 admissions.
    • Post-discharge survivorship and complications/outcomes cohorts tracking late effects and health service use after uncomplicated inpatient treatment: longitudinal observational studies follow patients who had ear, nose, mouth, and throat malignancies treated without major complications to capture rates of late functional impairment, ostomy or feeding tube dependence, secondary procedures, outpatient therapy needs, and unplanned readmissions. These studies clarify long-term quality-of-life trajectories and cumulative healthcare utilization for a population initially classified as DRG 148, informing follow-up care standards, rehabilitation referral timing, and payer projections of downstream costs beyond the index hospitalization.

    Related Codes

    135-SINUS-AND-MASTOID-PROCEDURES-WITH-CC-MCC

    Sinus and Mastoid Procedures with CC/MCC: Inpatient Reimbursement Overview

    136-SINUS-AND-MASTOID-PROCEDURES-WITHOUT-CC-MCC

    Sinus and Mastoid Procedures without CC/MCC: Inpatient Reimbursement Overview

    137-MOUTH-PROCEDURES-WITH-CC-MCC

    Mouth Procedures with CC/MCC: Inpatient Reimbursement Overview

    138-MOUTH-PROCEDURES-WITHOUT-CC-MCC

    Mouth Procedures without CC/MCC: Inpatient Reimbursement Overview

    139-SALIVARY-GLAND-PROCEDURES

    Salivary Gland Procedures: Inpatient Reimbursement Overview

    140-MAJOR-HEAD-AND-NECK-PROCEDURES-WITH-MCC

    Major Head and Neck Procedures with MCC: Inpatient Reimbursement Overview

    141-MAJOR-HEAD-AND-NECK-PROCEDURES-WITH-CC

    Major Head and Neck Procedures with CC: Inpatient Reimbursement Overview

    142-MAJOR-HEAD-AND-NECK-PROCEDURES-WITHOUT-CC-MCC

    Major Head and Neck Procedures without CC/MCC: Inpatient Reimbursement Overview

    143-OTHER-EAR-NOSE-MOUTH-AND-THROAT-O-R-PROCEDURES-WITH-MCC

    Other Ear, Nose, Mouth and Throat O.R. Procedures with MCC: Inpatient Reimbursement Overview

    144-OTHER-EAR-NOSE-MOUTH-AND-THROAT-O-R-PROCEDURES-WITH-CC

    Other Ear, Nose, Mouth and Throat O.R. Procedures with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 24

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.